Document is current
Any future updates will be listed below
-
Authors
Kitamura, Mineaki
Takazono, Takahiro https://orcid.org/0000-0002-0696-5386
Hosogaya, Naoki https://orcid.org/0000-0002-3229-2277
Morimoto, Shimpei
Kinoshita, Masahiro
Hamada, Eriko
Shimizu, Ryosuke https://orcid.org/0000-0001-9666-8678
Miyazawa, Shogo
Tanaka, Shintaro
Nishino, Tomoya
Mukae, Hiroshi
-
Funding
Funding for this research was provided by:
Shionogi and Co., Ltd
- License Information
-
More Information
Article History
Received: 28 November 2025
Accepted: 20 February 2026
First Online: 1 April 2026
Declarations
:
: Takahiro Takazono has received personal fees from Shionogi & Co., Ltd., MSD Co., Ltd., Pfizer Inc., Insmed Japan, Asahi Kasei Pharma Corporation, and Kyorin Pharmaceutical Co., Ltd. Naoki Hosigaya has no COI to disclose. Tomoya Nishino, Shimpei Morimoto, Mineaki Kitamura, and Hiroshi Mukae received personal fees from Shionogi & Co., Ltd., MSD Co., Ltd., Gilead Science, AstraZeneca K.K., Pfizer Inc., and GSK. Masahiro Kinoshita, Eriko Hamada, Ryosuke Shimizu, Shogo Miyazawa, and Shintaro Tanaka are employees of Shionogi & Co., Ltd. and its subsidiary.
: The trial was conducted in accordance with the Declaration of Helsinki and Japan’s Clinical Research Act. Ethical approval was obtained from the Nagasaki University Clinical Research Review Committee (CRB24-006). Written informed consent was obtained from all patients prior to any study-related procedure, and confidentiality was maintained using unique identifiers and secure EDC systems.
